Acetic Acid

Acetic Acid

SCHEMBL1170525

CC(=O)O.CCN(CC)OC(C)=O

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.38
LMNA P02545 1/20 0.38
HSD17B10 Q99714 1/20 0.38
FFAR3 O14843 2/20 0.37
LCK P06239 1/20 0.37
FYN P06241 1/20 0.37
TSHR P16473 2/20 0.32
TDP1 Q9NUW8 1/20 0.32
ALOX15 P16050 1/20 0.30
KDM6B O15054 1/20 0.30
KDM5C P41229 1/20 0.30
EGLN1 Q9GZT9 1/20 0.30
PHF8 Q9UPP1 1/20 0.30
KDM2A Q9Y2K7 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid SCHEMBL28716667 1.00 ALDH1A1 (0.38) ALDH1A1LMNAHSD17B10FFAR3LCK
SCHEMBL1683664 0.95
SCHEMBL27948229 0.92 ALDH1A1 (0.39) ALDH1A1LMNAHSD17B10TSHRTDP1
SCHEMBL27845804 0.92 ALDH1A1 (0.39) ALDH1A1LMNAHSD17B10TSHRTDP1
Hydrochloric Acid SCHEMBL28250755 0.92 ALDH1A1 (0.39) ALDH1A1LMNAHSD17B10TSHRTDP1
SCHEMBL28781241 0.92 ALDH1A1 (0.39) ALDH1A1LMNAHSD17B10TSHRTDP1
Ammonia Solution, Strong SCHEMBL28026699 0.92 ALDH1A1 (0.39) ALDH1A1LMNAHSD17B10TSHRTDP1
SCHEMBL27824742 0.85 ALDH1A1 (0.35) ALDH1A1LMNAHSD17B10
Acetoacetic Acid SCHEMBL27726728 0.84 KDM4E (0.35) ALDH1A1LMNAHSD17B10FFAR3TDP1
SCHEMBL662739 0.78 LMNA (0.48) ALDH1A1LMNAHSD17B10TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101927002-B Medicament and coating composition ZHONG SHUGUANG 2014-03-12 CN claimed
CN-103432091-A Improved-performance tablet and preparation method thereof ZHONG SHUGUANG 2013-12-11 CN claimed
CN-101987081-B Controlled release preparation SHUGUANG ZHONG 2012-08-08 CN claimed
CN-102000344-A Medicament coating composition with masked taste SHUGUANG ZHONG 2011-04-06 CN claimed
CN-101987081-A Controlled release preparation SHUGUANG ZHONG 2011-03-23 CN claimed
CN-101985044-A Taste-masking medicinal coating composition SHUGUANG ZHONG 2011-03-16 CN claimed
CN-101927002-A Medicament and coating composition SHUGUANG ZHONG 2010-12-29 CN claimed
US-5008118-A Contacting coating agent with core powder of organic material with sufficient frictional heating to cause adhesion NIPPON OIL AND FATS (JP) 1991-04-16 US claimed
EP-3826619-A1 PHARMACEUTICAL DOSAGE FORM WHICH CAN BE ADMINISTERED ORALLY AND HAS MODIFIED RELEASE Bayer Aktiengesellschaft (DE) 2021-06-02 EP disclosed
EP-3826627-A1 PHARMACEUTICAL DOSAGE FORM WHICH CAN BE ADMINISTERED ORALLY AND HAS MODIFIED RELEASE Bayer Aktiengesellschaft (DE) 2021-06-02 EP disclosed
WO-2020020790-A1 PHARMACEUTICAL DOSAGE FORM WHICH CAN BE ADMINISTERED ORALLY AND HAS MODIFIED RELEASE BAYER AKTIENGESELLSCHAFT (DE) 2020-01-30 WO disclosed
WO-2020020789-A1 PHARMACEUTICAL DOSAGE FORM WHICH CAN BE ADMINISTERED ORALLY AND HAS MODIFIED RELEASE BAYER AKTIENGESELLSCHAFT (DE) 2020-01-30 WO disclosed
EP-2392326-B9 Silibinin component for the treatment of hepatitis MADAUS GMBH (DE) 2018-09-05 EP disclosed
EP-2392326-B1 Silibinin component for the treatment of hepatitis MADAUS GMBH (DE) 2018-01-24 EP disclosed
EP-0335560-A2 Controlled release pharmaceutical preparation and method for producing the same Tanabe Seiyaku Co., Ltd. (JP) 1989-10-04 EP disclosed
US-4842863-A PHYSIOLOGICALLY ACTIVE SUBSTANCE COATED WITH A THIN FILM OF WAXY SUBSTANCE CONTAINING A SOLID AUXILIARY SUBSTANCE SHOWA DENKO KABUSHIKI KAISHA (JP) 1989-06-27 US disclosed
EP-0276781-A2 Granular agent for ruminant and production method thereof SHOWA DENKO KABUSHIKI KAISHA (JP) 1988-08-03 EP disclosed
US-4285987-A Process for manufacturing device with dispersion zone ALZA CORPORATION (US) 1981-08-25 US disclosed
US-4200098-A Osmotic system with distribution zone for dispensing beneficial agent ALZA CORPORATION (US) 1980-04-29 US disclosed
US-4160020-A CELLULOSE ESTERS, CELLULOSE ETHERS ALZA CORPORATION (US) 1979-07-03 US disclosed